ClinicalTrials.gg
RecruitingNCT06113276CT4ARDS-2Updated Jan 31, 2024

Quantitative Computed Tomography for Mortality Risk Stratification in ARDS

An observational study in Acute Respiratory Distress Syndrome, sponsored by Hospices Civils de Lyon. Recruiting at 4 sites in France. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2024-01-31.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
210
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Respiratory Distress Syndrome by Hospices Civils de Lyon — 2 open to participants now, 2 under way, none of them phase 3. Respiratory Distress Syndrome · Hospices Civils de Lyon.

Started
2020
with 1 other
Observational
2 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Respiratory Distress Syndrome by Hospices Civils de Lyon, this one is one of 2 that started in 2020, is one of 2 observational ones, and was the 15th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

2 of the 15 studies in Respiratory Distress Syndrome by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Respiratory Distress Syndrome by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Acute respiratory distress syndrome remains a deadly disease with hospital mortality remaining between 40 to 50%. ARDS mortality risk factors have been identified from patient history, common clinical and biological variables in the lung SAFE study. Part of ARDS mortality is attributable to ventilator-induced lung injury (VILI), in relation with inappropriate settings on the ventilator. Tidal hyperinflation and recruitment/derecruitment during lung inflation are 2 identified mechanisms leading to VILI, that may be identified on computed tomography while poorly identified with variables collected at the bedside.

The aim of this study is to identify whether tidal hyperinflation identified on computed tomography is a risk factor for ARDS mortality, independently from know bio-clinical risk factors.

03

Conditions studied

  • Acute Respiratory Distress Syndrome

Keywords

  • ARDS
  • computed tomography
  • alveolar recruitment
  • PEEP
  • tidal hyperinflation
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be screened from the population of patient hospitalized for ARDS in the participating centers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 15 or older with ARDS according to the Berlin definition
  • invasive mechanical ventilation with PaO2/FiO2 ≤ 300 mm Hg
  • with computed tomography acquired at both end-expiration and end-inspiration, or at both PEEP 5 and 15 cm H2O at end-expiration
  • PEEP setting according to a PEEP/FiO2 table, with secondary adjustment according to hemodynamic tolerance
  • Tidal volume 6 ml/kg of predicted body weight or less

Exclusion criteria

Exclusion Criteria:

  • Use of contrast agent during computed tomography acquisition
  • ARDS criteria onset since more than 72 hours or ECMO onset since more than 72 hours
  • Proven
  • Pneumothorax or bronchopleural fistula
  • Patient with spontaneous breathing preventing realization of end-expiratory and end-inspiratory pauses
  • Previous inclusion in current study
  • Patient under a legal protective measure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
210 participants (estimated)
Patient registry
No

Groups and cohorts

  • tidal hyperinflation

    As the study aim to identify whether tidal hyperinflation is an independent predictor for ARDS mortality, and as this variable will be entered as a quantitative predictor in the multivariate model, the study encompass a single group of patient (i.e. all included patients)

    Radiation: Low dose computed tomography to evaluate biomechanical parameters in the lung

Interventions

  • RadiationLow dose computed tomography to evaluate biomechanical parameters in the lung

    In the participating to the study, response to PEEP increase and tidal inflation are evaluated with a software computing biomechanical parameters (tidal hyperinflation and lung recruitability). Tidal hyperinflation and recruitment are computed on CT images acquired within 72 hours after ARDS onset or with 72h after ECMO onset.

06

What researchers measure

Primary outcomes

  1. Odd ratio of tidal hyperinflation assessed on CT at day-0 as an independent predictor of 90-day mortality

    Tidal hyperinflation is computed as the volume difference of hyperinflated lung (i.e., with CT attenuation between -1000 and -900 Hounsfield units) between and-expiration and end-inspiration at the PEEP level chosen by clinician

    Time frame: Day-0 (time of realization of CT scan)

07

Study locations

4 of 4 sites recruiting
  • Service de Médecine Intensive Réanimation Hôpital Michallon - CHU Grenoble Alpes
    La Tronche, 38700, France
    Recruiting
    • Nicolas TERZI, Pr · Contactnterzi@chu-grenoble.fr · 04-76-76-87-79
    • Nicolas TERZI, Pr · Principal investigator
  • Hospices Civils de Lyon - Hôpital de la Croix Rousse - Service de Médecine Intensive Réanimation
    Lyon, 69004, France
    Recruiting
  • Service de Réanimation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon
    Pierre-Bénite, 69310, France
    Recruiting
  • Centre Hospitalier Universitaire de Rennes
    Rennes, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Nov 2024, 47 months after the start.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 47 months is above that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2023
First posted
Nov 2, 2023
StartActual
Nov 6, 2020
Primary completionEst.
Nov 1, 2024
CompletionEst.
May 1, 2025
Last update
Jan 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06113276
Responsible party
Sponsor
First posted
Nov 2, 2023
Start date
Nov 6, 2020
Primary completion
Nov 1, 2024 (estimated)
Completion
May 1, 2025 (estimated)
Last update
Jan 31, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion